RVL Pharmaceuticals plc
Index- P/E- EPS (ttm)-0.62 Insider Own3.60% Shs Outstand92.76M Perf Week-15.00%
Market Cap100.43M Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float48.45M Perf Month-23.31%
Income-53.00M PEG- EPS next Q-0.16 Inst Own49.90% Short Float / Ratio0.29% / 2.57 Perf Quarter-19.05%
Sales42.80M P/S2.35 EPS this Y6.30% Inst Trans50.27% Short Interest0.14M Perf Half Y-63.04%
Book/sh0.74 P/B1.45 EPS next Y16.40% ROA-37.30% Target Price3.68 Perf Year-49.25%
Cash/sh0.64 P/C1.68 EPS next 5Y- ROE-77.70% 52W Range0.99 - 2.99 Perf YTD-8.93%
Dividend- P/FCF- EPS past 5Y-8.50% ROI-67.60% 52W High-65.89% Beta1.08
Dividend %- Quick Ratio3.30 Sales past 5Y-39.60% Gross Margin81.30% 52W Low3.03% ATR0.12
Employees156 Current Ratio3.30 Sales Q/Q354.50% Oper. Margin- RSI (14)38.46 Volatility16.79% 9.07%
OptionableYes Debt/Eq0.82 EPS Q/Q62.80% Profit Margin- Rel Volume1.96 Prev Close1.07
ShortableYes LT Debt/Eq0.82 EarningsMar 20 BMO Payout- Avg Volume55.59K Price1.02
Recom2.20 SMA20-14.79% SMA50-16.75% SMA200-35.39% Volume12,610 Change-4.67%
Oct-21-22Resumed Jefferies Hold $2.50
Mar-21-23 05:32AM
Mar-20-23 11:11PM
Mar-15-23 06:50AM
Feb-23-23 09:32AM
07:18AM Loading…
Feb-03-23 07:18AM
Jan-27-23 09:18AM
Jan-09-23 06:50AM
Dec-31-22 09:08AM
Dec-08-22 08:08AM
Dec-01-22 08:57AM
Nov-14-22 04:22AM
Nov-10-22 04:05PM
Nov-03-22 04:05PM
Oct-18-22 06:50AM
04:05PM Loading…
Aug-30-22 04:05PM
Aug-14-22 10:18AM
Aug-11-22 06:50AM
Aug-04-22 05:06PM
Jul-24-22 10:01AM
Jul-07-22 02:40PM
Jul-01-22 08:34AM
Jun-16-22 04:05PM
May-16-22 06:50AM
May-12-22 06:50AM
May-09-22 08:06AM
May-05-22 01:00PM
08:33AM Loading…
Apr-06-22 08:33AM
Mar-30-22 04:05PM
Mar-23-22 04:45PM
Mar-09-22 04:30PM
Feb-17-22 01:16PM
Jan-19-22 11:38AM
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.